Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

zirconium Zr 89-DFO-SC16.56

A radioimmunoconjugate composed of SC16.56, a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3; delta like canonical notch ligand 3; drosophila delta homolog 3; delta3; delta-like 3; SCDO1), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration of zirconium Zr 89-DFO-SC16.56, the monoclonal antibody moiety specifically targets and binds to DLL3. Upon binding, the radioisotope moiety is detected using PET, thereby allowing the imaging and quantification of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Synonym:89Zr-DFO-SC16.56
Search NCI's Drug Dictionary